This database contains 8 studies, archived under the term: "Alzheimer Disease Assessment"
Rivastigmine for cognitive impairment after spontaneous subarachnoid haemorrhage: A pilot study
Wong, G. K. C.,
Wong, R.,
Mok, V.,
Wong, A.,
Fan, D.,
Leung, G.,
Chan, A.,
Poon, W. S.
Background and objective: Rivastigmine has been shown to be effective for patients with mild-to-moderate Alzheimer’s disease. Its effect on cognitive impairment after aneurysmal subarachnoid haemorrhage has not been previously studied. The aim of the study is to evaluate the efficacy and safety of rivastigmine 3 mg day over 12 weeks in patients with aneurysmal subarachnoid […]
Cognitive intervention response is related to habitual physical activity in older adults
Thiel, Christian,
Vogt, Lutz,
Tesky, Valentina A.,
Meroth, Linda,
Jakob, Marion,
Sahlender, Sandra,
Pantel, Johannes,
Banzer, Winfried
Background and Aims: This study analysed the associations between physical activity and the effects of cognitive training on perceived cognitive functioning and life satisfaction in older adults.; Methods: A sample of 114 intervention group participants (65-89 yrs) received weekly group sessions of cognitive stimulation for two months. This sample was stratified into groups according to […]
A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer’s disease
Pasqualetti, Patrizio,
Bonomini, Cristina,
Dal Forno, Gloria,
Paulon, Luca,
Sinforiani, Elena,
Marra, Camillo,
Zanetti, Orazio,
Rossini, Paolo Maria
Background and Aims: Epidemiological studies have examined the association between the use of non-steroidal anti-inflammatory drugs (NSAIDs) and the risk of Alzheimer’s disease (AD). Recently, a variety of experimental studies indicates that a subset of NSAIDs, such as ibuprofen or flurbiprofen, also have Abeta-lowering properties in both AD transgenic mice and cell cultures of peripheral, […]
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial
Green, Robert C.,
Schneider, Lon S.,
Amato, David A.,
Beelen, Andrew P.,
Wilcock, Gordon,
Swabb, Edward A.,
Zavitz, Kenton H.
Context: Amyloid-beta peptide (Abeta(42)) has been implicated in the pathogenesis of Alzheimer disease (AD). Tarenflurbil, a selective Abeta(42)-lowering agent, demonstrated encouraging results on cognitive and functional outcomes among mildly affected patients in an earlier phase 2 trial.; Objective: To determine the efficacy, safety, and tolerability of tarenflurbil.; Design, Setting, and Patients: A multicenter, randomized, double-blind, […]
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial
Doody, R. S.,
Ferris, S. H.,
Salloway, S.,
Sun, Y.,
Goldman, R.,
Watkins, W. E.,
Xu, Y.,
Murthy, A. K.
Background: Treatment of mild cognitive impairment (MCI) with cholinesterase inhibitors may improve symptoms.; Methods: In this multicenter, randomized, placebo-controlled trial, subjects with MCI entered a 3-week placebo run-in period followed by 48 weeks of double-blind donepezil (5 mg/day for 6 weeks, then 10 mg/day for 42 weeks) or placebo treatment. Primary efficacy variables included change […]
Visual evoked potentials to pattern, motion and cognitive stimuli in Alzheimer’s disease
Kubová, Z.,
Kremlácek, J.,
Valis, M.,
Langrová, J.,
Szanyi, J.,
Vít, F.,
Kuba, M.
The aim of our study was to verify reported visual dysfunctions of patients with Alzheimer disease with the use of several variants of VEPs and visual ERPs and to learn whether these methods can be useful in diagnostics of AD. We tested 15 patients (6 women and 9 men, aged from 58 to 87) with […]
A randomized, placebo-controlled trial of latrepirdine in Huntington disease
Kieburtz, Karl,
McDermott, Michael P.,
Voss, Tiffini S.,
Corey-Bloom, Jody,
Deuel, Lisa M.,
Dorsey, E. Ray,
Factor, Stewart,
Geschwind, Michael D.,
Hodgeman, Karen,
Kayson, Elise,
Noonberg, Sarah,
Pourfar, Michael,
Rabinowitz, Karen,
Ravina, Bernard,
Sanchez-Ramos, Juan,
Seely, Lynn,
Walker, Francis,
Feigin, Andrew
Objectives: To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms.; Design: Double-blind, randomized, placebo-controlled trial.; Setting: Multicenter outpatient trial.; Participants: Ninety-one participants with mild to moderate HD enrolled at 17 US and UK centers from July 18, 2007, through July 16, 2008.; […]